Diligence memo · auto-generated · as of July 2, 2026

Definitive Biotechnologies LLC

Definitive Biotechnologies LLC looks under-valued against its niche peers and is at-risk on financing cadence.

WatchOverdue for a raise versus sector cadence — could be a bridge, a down round, or distress. Watch for the next filing.

Businessfiled

Definitive Biotechnologies LLC operates in Biotech / Pharma, based in ELKRIDGE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Definitive Biotechnologies LLC has raised $5.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $4.3M on 2021-04-06.

Most recent recorded round closed around 2023-03-31.

Valuation (modeled)modeled

Provath models Definitive Biotechnologies LLC at approximately $8.4M (range $1.0M–$24M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.22× the median modeled value of Series A Biotech / Pharma companies in 2022–2024 (21 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 12 months.

Last raise 3.3 yr ago; this sector typically re-raises about every 15 months.

Past due for a raise versus sector cadence — watch for distress or a bridge.

The last round was 4.8× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 51% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 32% of those peers.

Closest niche peers: Laxmi Therapeutic Devices, Inc., Accipiter Biosciences Inc., Nanospectra Biosciences Inc, Ten Bay Bio, Inc., Genomic Life, Inc..

Peoplefiled

1 named person on file across officers, directors and signatories.

Risks & flagsmixed

Overdue for a raise versus sector norm — distress or bridge risk.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.